Company profile: Strata Oncology
1.1 - Company Overview
Company description
- Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
Products and services
- Immunotherapy Response Score (IRS): Diagnostic tool that predicts benefit of anti-PD-1/PD-L1 monotherapy by integrating tumor mutation burden with expression of specific genes to guide checkpoint inhibitor use
- Strata Select: Molecular profiling test for advanced cancer patients that combines DNA and RNA sequencing to deliver treatment selection guidance for immunotherapy and other therapies
- Strata Trial: Large-scale observational trial that delivers tumor sequencing and access to approved and investigational precision therapies for patients with advanced cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Strata Oncology
QuanDx
HQ: United States
Website
- Description: Provider of life science reagents and molecular diagnostic kits, including the Q-Fusion multiplex system and Q30 screening kit for leukemia fusion genes, Yin-Yang Probes for affordable, multiplexed tests for various diseases, and a High Risk HPV Genotyping Assay detecting 14 types of high-risk HPV with automatic result interpretation in a single tube reaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QuanDx company profile →
Krystal Biotech
HQ: United States
Website
- Description: Provider of gene therapies, including FDA-approved VYJUVEK for delivering missing or defective genes to the skin; with focus on Autosomal Recessive Congenital Ichthyosis, Netherton Syndrome, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency; and oncology development using a modified HSV-1 vector to deliver IL-12 and IL-2 to the tumor microenvironment for immune-mediated tumor clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Krystal Biotech company profile →
Tome Biosciences
HQ: United States
Website
- Description: Provider of programmable gene insertion technologies, including Integrase-Mediated PGI using a proprietary integrase to integrate large DNA sequences (>1,000 bp) at user-defined genomic locations and Ligase-Mediated PGI using a DNA ligase for small sequence insertion, plus integrative gene therapies for PKU (PAH), ASCVD (ApoA-1), HCU (CBS), and hereditary hemochromatosis (HFE).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tome Biosciences company profile →
Arivale
HQ: United States
Website
- Description: Provider of a scientific path for individuals to optimize wellness and avoid disease for a life filled with joyful moments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arivale company profile →
Diagnoplex
HQ: Switzerland
Website
- Description: Provider of non-invasive colorectal cancer screening tests and diagnostics, including the COLOX colorectal cancer screening test; the company has conducted a 140-patient prospective pilot study demonstrating technical and clinical feasibility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnoplex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Strata Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Strata Oncology
2.2 - Growth funds investing in similar companies to Strata Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Strata Oncology
4.2 - Public trading comparable groups for Strata Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →